Neurosciences encompasses a broad range of research from the molecular (e.g. aptamer research) to clinical (e.g. research into concussion from sports).
Our goal is to be internationally recognized in 3 areas (neuro-oncology, dementia and neurodegeneration and molecular psychiatry). We have a bench to bedside approach capitalizing on our quite unique staff profile ranging from basic biomedical scientists through pharmaceutics to clinicians.
We also focus on collaborations with our local charities and a network of researchers and clinicians across the world.
We have a significant local impact in our neuro-oncology research. One strand of our Molecular Psychiatry group is research into legal highs and this research has had an impact on the government drug policy. Our Dementia and Neurodegeneration group is funded by the company.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
10
Feb 2026
Case Western Reserve University researchers have made a significant breakthrough in understanding Barrett's esophagus, a precancerous condition that dramatically increases the risk of developing esophageal adenocarcinoma, one of the fastest-spreading and deadliest forms of cancer.
10
Feb 2026
A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."
10
Feb 2026
A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."
10
Feb 2026
A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC."